Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Intranasal Naltrexone and Naloxone
NCT03851731Phase 1Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of naltrexone transdermal patch and naloxone in opioid overdose (3 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Maximum Serum Concentration at 12 days, Area Under the Plasma Concentration Time Curve from Zero to Time t at 12 days and 1 more. Started Oct 2015; status: completed.
02
Drugs
naltrexone transdermal patchnaloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT03851731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851731.